CDER Publishes MaPP on Managing Financial Disclosures in NDAs, BLAs

Drug Industry Daily
A A
CDER’s Office of New Drugs established policies and procedures for review staff for the management of financial disclosure information submitted in NDAs, BLAs and supplemental applications.

To View This Article:

Login

Subscribe To Drug Industry Daily